Malcolm J. Moore

74.4k total citations · 13 hit papers
358 papers, 37.0k citations indexed

About

Malcolm J. Moore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Malcolm J. Moore has authored 358 papers receiving a total of 37.0k indexed citations (citations by other indexed papers that have themselves been cited), including 241 papers in Oncology, 128 papers in Pulmonary and Respiratory Medicine and 92 papers in Surgery. Recurrent topics in Malcolm J. Moore's work include Pancreatic and Hepatic Oncology Research (111 papers), Colorectal Cancer Treatments and Studies (86 papers) and Cancer Genomics and Diagnostics (65 papers). Malcolm J. Moore is often cited by papers focused on Pancreatic and Hepatic Oncology Research (111 papers), Colorectal Cancer Treatments and Studies (86 papers) and Cancer Genomics and Diagnostics (65 papers). Malcolm J. Moore collaborates with scholars based in Canada, United States and Australia. Malcolm J. Moore's co-authors include Dongsheng Tu, Mace L. Rothenberg, Daniel D. Von Hoff, Russell K. Portenoy, Steven Gallinger, M. Christine Cripps, Peter G. Tarassoff, Anna Maria Storniolo, John Sahl Andersen and Derek J. Jonker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Malcolm J. Moore

350 papers receiving 36.1k citations

Hit Papers

Improvements in survival and clinical benefit with gemcit... 1996 2026 2006 2016 1997 2007 2008 2000 2000 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    1997 4.6k citations Malcolm J. Moore, Mace L. Rothenberg et al. Journal of Clinical Oncology profile →
  2. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
    2007 2.9k citations Malcolm J. Moore, Wendy R. Parulekar et al. Journal of Clinical Oncology profile →
  3. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
    2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
  4. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
    2000 2.4k citations Malcolm J. Moore, Jean A. Maroun et al. profile →
  5. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
    2000 1.7k citations Malcolm J. Moore et al. Journal of Clinical Oncology profile →
  6. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
    2003 1.6k citations Malcolm J. Moore, Stanley R. Hamilton et al. profile →
  7. Cetuximab for the Treatment of Colorectal Cancer
    2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. profile →
  8. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
    2005 1.4k citations Malcolm J. Moore et al. Journal of Clinical Oncology profile →
  9. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
    2014 1.2k citations Camilla Zimmermann, Amit M. Oza et al. profile →
  10. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    1996 1.2k citations D. Scott Ernst, Malcolm J. Moore et al. Journal of Clinical Oncology profile →
  11. Advanced pancreatic carcinoma: current treatment and future challenges
    2010 641 citations Anastasios Stathis, Malcolm J. Moore Nature Reviews Clinical Oncology profile →
  12. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    2009 504 citations Sharlene Gill, Malcolm J. Moore et al. Journal of Clinical Oncology profile →
  13. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
    2011 402 citations Malcolm J. Moore et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Malcolm J. Moore Canada 72 25.0k 10.6k 9.5k 7.6k 7.3k 358 37.0k
Patrick Maisonneuve Italy 108 17.1k 0.7× 7.2k 0.7× 12.2k 1.3× 6.2k 0.8× 10.4k 1.4× 567 41.9k
Leonard B. Saltz United States 105 28.0k 1.1× 9.6k 0.9× 10.3k 1.1× 6.6k 0.9× 4.2k 0.6× 544 38.3k
Al B. Benson United States 94 18.9k 0.8× 8.7k 0.8× 8.7k 0.9× 3.5k 0.5× 5.5k 0.8× 492 31.0k
Bengt Glimelius Sweden 92 30.4k 1.2× 9.9k 0.9× 18.0k 1.9× 3.4k 0.4× 3.3k 0.5× 700 41.7k
John D. Hainsworth United States 82 21.5k 0.9× 12.3k 1.2× 5.3k 0.6× 10.1k 1.3× 5.2k 0.7× 631 37.1k
Carsten Bokemeyer Germany 89 14.2k 0.6× 9.8k 0.9× 11.6k 1.2× 9.5k 1.3× 3.0k 0.4× 957 36.1k
Richard Pazdur United States 106 19.8k 0.8× 10.3k 1.0× 3.8k 0.4× 10.6k 1.4× 5.2k 0.7× 596 37.7k
Richard M. Goldberg United States 85 24.0k 1.0× 8.3k 0.8× 6.9k 0.7× 5.0k 0.7× 4.9k 0.7× 531 33.3k
Armando Santoro Italy 87 17.8k 0.7× 13.8k 1.3× 3.8k 0.4× 5.6k 0.7× 3.8k 0.5× 924 34.7k
Everett E. Vokes United States 95 19.2k 0.8× 15.5k 1.5× 7.6k 0.8× 9.6k 1.3× 3.2k 0.4× 774 36.3k

Countries citing papers authored by Malcolm J. Moore

Since Specialization
Citations

This map shows the geographic impact of Malcolm J. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm J. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm J. Moore more than expected).

Fields of papers citing papers by Malcolm J. Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm J. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm J. Moore. The network helps show where Malcolm J. Moore may publish in the future.

Co-authorship network of co-authors of Malcolm J. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm J. Moore. A scholar is included among the top collaborators of Malcolm J. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm J. Moore. Malcolm J. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gupta, Arjun, Christopher J. O’Callaghan, Liting Zhu, et al.. (2024). The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17. JNCI Journal of the National Cancer Institute. 116(8). 1313–1318. 7 indexed citations
2.
Titmuss, Emma, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research. 30(6). 1121–1130. 3 indexed citations
3.
Chen, Nan, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2023). Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.. Journal of Clinical Oncology. 41(4_suppl). 124–124. 1 indexed citations
4.
Loree, Jonathan M., Dongsheng Tu, Derek J. Jonker, et al.. (2020). Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research. 27(1). 52–59. 19 indexed citations
5.
Lewin, Jeremy, Laleh Soltan Ghoraie, Philippe L. Bédard, et al.. (2018). Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. British Journal of Urology. 122(5). 814–822. 8 indexed citations
6.
Hosni, Ali, Padraig Warde, Michael A.S. Jewett, et al.. (2016). Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma. Clinical Oncology. 28(10). 648–654. 12 indexed citations
7.
Hobday, Timothy J., Rui Qin, Diane Reidy‐Lagunes, et al.. (2014). Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. Journal of Clinical Oncology. 33(14). 1551–1556. 96 indexed citations
8.
Richter, Suzanne, Jo-An Seah, Gregory R. Pond, et al.. (2014). Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Canadian Urological Association Journal. 8(11-12). 398–398. 2 indexed citations
9.
Lo, Christopher, Andrew Calzavara, Paul Kurdyak, et al.. (2013). Depression and use of health care services in patients with advanced cancer.. PubMed. 59(3). e168–74. 20 indexed citations
10.
Tang, Patricia A., Steven J. Cohen, Christian Kollmannsberger, et al.. (2012). Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 18(21). 6023–6031. 67 indexed citations
11.
Gauthier, Lynn R., Gary Rodin, Camilla Zimmermann, et al.. (2012). The Communal Coping Model and Cancer Pain: The Roles of Catastrophizing and Attachment Style. Journal of Pain. 13(12). 1258–1268. 34 indexed citations
12.
Stathis, Anastasios & Malcolm J. Moore. (2010). Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology. 7(3). 163–172. 641 indexed citations breakdown →
13.
Sridhar, Srikala S., Christina M. Canil, Kim N., et al.. (2010). A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 67(4). 927–933. 21 indexed citations
14.
Santos, Gilda da Cunha, Neesha C. Dhani, Dongsheng Tu, et al.. (2010). Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer. 116(24). 5599–5607. 117 indexed citations
15.
Tse, Rachel L.S., Laura A. Dawson, Alice C. Wei, & Malcolm J. Moore. (2007). Neoadjuvant treatment for pancreatic cancer—A review. Critical Reviews in Oncology/Hematology. 65(3). 263–274. 21 indexed citations
16.
Sridhar, Srikala S., Mary J. MacKenzie, Sébastien J. Hotte, et al.. (2007). AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.. Molecular Cancer Therapeutics. 6. 1 indexed citations
17.
Le, Lyly, Malcolm J. Moore, Lillian L. Siu, et al.. (2005). Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 56(2). 154–160. 27 indexed citations
18.
Bjarnason, Georg A., C. Cripps, Rakesh Goel, et al.. (1998). Phase I-II Study of 5-Fluorouracil, Leucovorin, Doxorubicin, Methotrexate, and Long-Term Oral Etoposide (FLAME) in Unresectable or Metastatic Gastric Cancer. American Journal of Clinical Oncology. 21(6). 537–542.
19.
Moore, Malcolm J., Ian F. Tannock, D. Scott Ernst, S. Huan, & Nevin Murray. (1997). Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.. Journal of Clinical Oncology. 15(12). 3441–3445. 222 indexed citations
20.
Rothenberg, Mace L., James L. Abbruzzese, Malcolm J. Moore, et al.. (1996). A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 78(S3). 627–632. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Maisonneuve Breakdown of academic impact, for papers by Leonard B. Saltz Breakdown of academic impact, for papers by Al B. Benson Breakdown of academic impact, for papers by Bengt Glimelius Breakdown of academic impact, for papers by John D. Hainsworth Breakdown of academic impact, for papers by Carsten Bokemeyer Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Richard M. Goldberg Breakdown of academic impact, for papers by Armando Santoro Breakdown of academic impact, for papers by Everett E. Vokes
Rankless by CCL
2026